TRiCares SAS

Based in France, TRiCares SAS develops innovative medical technology specifically targeting tricuspid regurgitation through its catheter-based solution, the Topaz device, enhancing treatment options for cardiac patients. TRiCares SAS, founded in 2013, is headquartered in Paris, France, and focuses on the development of medical technology for cardiac conditions. The company has successfully completed 8 deals, with its most recent transaction occurring on July 25, 2024, involving a Series D funding round that raised USD 5. 000 mn, bringing the total amount raised to USD 5.

000 mn. The founder's history is not provided, but the company has remained focused on its core mission since inception. TRiCares SAS specializes in innovative medical technology aimed at addressing tricuspid regurgitation (TR). Its flagship product, the Topaz device, is a catheter-based tricuspid valve replacement system that offers a minimally invasive treatment option, designed for safety, user-friendliness, and quick procedures.

The device targets a global market, including the United States, Europe, and Brazil, and is utilized by hospitals and medical institutions for the treatment of cardiac patients, primarily cardiologists and those needing surgical intervention for tricuspid valve disorders. TRiCares SAS operates through direct sales to healthcare providers such as hospitals and medical centers. The revenue model is transaction-based, contingent on device purchases, with potential long-term partnerships for ongoing supply. The company posted an EBITDA of -USD 9,653,732.

60 in 2021, reflecting its ongoing investment in clinical advancements and market presence. Its successful Series D funding of USD 5. 000 mn illustrates its strategy to enhance product availability and support market demand for advanced treatment options for tricuspid regurgitation. In July 2024, TRiCares SAS raised USD 50 million in Series D funding, which will be utilized to support the development of the Topaz heart valve prosthesis and its implantation system, along with upcoming clinical milestones.

The company aims to expand into new markets, specifically targeting additional regions within Europe and South America by late 2025, enhancing its reach in addressing the needs of patients with tricuspid regurgitation.